Literature DB >> 23303066

Enhanced histaminergic neurotransmission and sleep-wake alterations, a study in histamine H3-receptor knock-out mice.

Elise Gondard1, Christelle Anaclet, Hidéo Akaoka, Rui-Xian Guo, Mei Zhang, Colette Buda, Patricia Franco, Hidehito Kotani, Jian-Sheng Lin.   

Abstract

Long-term abolition of a brain arousal system impairs wakefulness (W), but little is known about the consequences of long-term enhancement. The brain histaminergic arousal system is under the negative control of H3-autoreceptors whose deletion results in permanent enhancement of histamine (HA) turnover. In order to determine the consequences of enhancement of the histaminergic system, we compared the cortical EEG and sleep-wake states of H3-receptor knockout (H3R-/-) and wild-type mouse littermates. We found that H3R-/-mice had rich phenotypes. On the one hand, they showed clear signs of enhanced HA neurotransmission and vigilance, i.e., a higher EEG θ power during spontaneous W and a greater extent of W or sleep restriction during behavioral tasks, including environmental change, locomotion, and motivation tests. On the other hand, during the baseline dark period, they displayed deficient W and signs of sleep deterioration, such as pronounced sleep fragmentation and reduced cortical slow activity during slow wave sleep (SWS), most likely due to a desensitization of postsynaptic histaminergic receptors as a result of constant HA release. Ciproxifan (H3-receptor inverse agonist) enhanced W in wild-type mice, but not in H3R-/-mice, indicating a functional deletion of H3-receptors, whereas triprolidine (postsynaptic H1-receptor antagonist) or α-fluoromethylhistidine (HA-synthesis inhibitor) caused a greater SWS increase in H3R-/- than in wild-type mice, consistent with enhanced HA neurotransmission. These sleep-wake characteristics and the obesity phenotypes previously reported in this animal model suggest that chronic enhancement of histaminergic neurotransmission eventually compromises the arousal system, leading to sleep-wake, behavioral, and metabolic disorders similar to those caused by voluntary sleep restriction in humans.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23303066      PMCID: PMC3629391          DOI: 10.1038/npp.2012.266

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  56 in total

Review 1.  Histamine H3 receptors and sleep-wake regulation.

Authors:  Jian-Sheng Lin; Olga A Sergeeva; Helmut L Haas
Journal:  J Pharmacol Exp Ther       Date:  2010-09-23       Impact factor: 4.030

2.  Modulation of hippocampal theta oscillation by histamine H3 receptors.

Authors:  M Hajós; C J Siok; W E Hoffmann; S Li; B Kocsis
Journal:  J Pharmacol Exp Ther       Date:  2007-10-16       Impact factor: 4.030

3.  Impact of sleep debt on metabolic and endocrine function.

Authors:  K Spiegel; R Leproult; E Van Cauter
Journal:  Lancet       Date:  1999-10-23       Impact factor: 79.321

4.  [Long-term recording of cerebral, muscular and ocular electric activities in mice].

Authors:  J L Valatx
Journal:  C R Seances Soc Biol Fil       Date:  1971

5.  Histamine and its receptors modulate temperature-preference behaviors in Drosophila.

Authors:  Sung-Tae Hong; Sunhoe Bang; Donggi Paik; Jongkyun Kang; Seungyoon Hwang; Keunhye Jeon; Bumkoo Chun; Seogang Hyun; Youngseok Lee; Jaeseob Kim
Journal:  J Neurosci       Date:  2006-07-05       Impact factor: 6.167

6.  Evidence for the role of histamine H3 receptor in alcohol consumption and alcohol reward in mice.

Authors:  Saara Nuutinen; Minnamaija Lintunen; Jenni Vanhanen; Tiia Ojala; Stanislav Rozov; Pertti Panula
Journal:  Neuropsychopharmacology       Date:  2011-06-08       Impact factor: 7.853

7.  BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology.

Authors:  X Ligneau; D Perrin; L Landais; J-C Camelin; T P G Calmels; I Berrebi-Bertrand; J-M Lecomte; R Parmentier; C Anaclet; J-S Lin; V Bertaina-Anglade; C Drieu la Rochelle; F d'Aniello; A Rouleau; F Gbahou; J-M Arrang; C R Ganellin; H Stark; W Schunack; J-C Schwartz
Journal:  J Pharmacol Exp Ther       Date:  2006-09-27       Impact factor: 4.030

8.  Histaminergic system in the cat hypothalamus with reference to type B monoamine oxidase.

Authors:  J S Lin; K Kitahama; P Fort; P Panula; R M Denney; M Jouvet
Journal:  J Comp Neurol       Date:  1993-04-15       Impact factor: 3.215

Review 9.  Rodent models of insomnia: a review of experimental procedures that induce sleep disturbances.

Authors:  Florent G Revel; Juergen Gottowik; Sylvia Gatti; Joseph G Wettstein; Jean-Luc Moreau
Journal:  Neurosci Biobehav Rev       Date:  2009-03-14       Impact factor: 8.989

10.  Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist.

Authors:  A J Barbier; C Berridge; C Dugovic; A D Laposky; S J Wilson; J Boggs; L Aluisio; B Lord; C Mazur; C M Pudiak; X Langlois; W Xiao; R Apodaca; N I Carruthers; T W Lovenberg
Journal:  Br J Pharmacol       Date:  2004-10-04       Impact factor: 8.739

View more
  16 in total

1.  Histamine H3 Receptor Antagonist Prevents Memory Deficits and Synaptic Plasticity Disruption Following Isoflurane Exposure.

Authors:  Tao Luo; Ying Wang; Jian Qin; Zhi-Gang Liu; Min Liu
Journal:  CNS Neurosci Ther       Date:  2017-02-06       Impact factor: 5.243

Review 2.  Histamine-4 Receptor: Emerging Target for the Treatment of Neurological Diseases.

Authors:  Ling Shan; Gerard J M Martens; Dick F Swaab
Journal:  Curr Top Behav Neurosci       Date:  2022

3.  Impact of Astroglial Connexins on Modafinil Pharmacological Properties.

Authors:  Adeline Duchêne; Magali Perier; Yan Zhao; Xinhe Liu; Julien Thomasson; Frédéric Chauveau; Christophe Piérard; Didier Lagarde; Christèle Picoli; Tiffany Jeanson; Franck Mouthon; Yves Dauvilliers; Christian Giaume; Jian-Sheng Lin; Mathieu Charvériat
Journal:  Sleep       Date:  2016-06-01       Impact factor: 5.849

Review 4.  Interactions of the histamine and hypocretin systems in CNS disorders.

Authors:  Ling Shan; Yves Dauvilliers; Jerome M Siegel
Journal:  Nat Rev Neurol       Date:  2015-06-23       Impact factor: 42.937

5.  Loss of Melanopsin Photoreception and Antagonism of the Histamine H3 Receptor by Ciproxifan Inhibit Light-Induced Sleep in Mice.

Authors:  Fanuel Muindi; Damien Colas; Jesse Ikeme; Norman F Ruby; H Craig Heller
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

6.  Histaminergic system in brain disorders: lessons from the translational approach and future perspectives.

Authors:  Diego Baronio; Taylor Gonchoroski; Kamila Castro; Geancarlo Zanatta; Carmem Gottfried; Rudimar Riesgo
Journal:  Ann Gen Psychiatry       Date:  2014-11-18       Impact factor: 3.455

7.  Ciproxifan, a histamine H3 receptor antagonist, reversibly inhibits monoamine oxidase A and B.

Authors:  S Hagenow; A Stasiak; R R Ramsay; H Stark
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

8.  Time-Restricted Feeding Improves Circadian Dysfunction as well as Motor Symptoms in the Q175 Mouse Model of Huntington's Disease.

Authors:  Huei-Bin Wang; Dawn H Loh; Daniel S Whittaker; Tamara Cutler; David Howland; Christopher S Colwell
Journal:  eNeuro       Date:  2018-01-03

9.  Chronic Toxoplasma gondii infection and sleep-wake alterations in mice.

Authors:  Damien Dupont; Jian-Sheng Lin; François Peyron; Hideo Akaoka; Martine Wallon
Journal:  CNS Neurosci Ther       Date:  2021-06-04       Impact factor: 5.243

Review 10.  Sites of action of sleep and wake drugs: insights from model organisms.

Authors:  Jason Rihel; Alexander F Schier
Journal:  Curr Opin Neurobiol       Date:  2013-05-23       Impact factor: 6.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.